Hans-Michael Hau1,2, Nora Jahn3, Maximilian Brunotte4,5, Andri Arnosson Lederer1, Elisabeth Sucher6, Franz Maximilian Rasche7, Daniel Seehofer1, Robert Sucher1. 1. Department of Visceral, Transplantation, Vascular and Thoracic Surgery, University Hospital of Leipzig, Liebigstrasse 20, 04103, Leipzig, Germany. 2. Department of Visceral, Transplantation, Vascular and Thoracic Surgery, University Hospital of Dresden, Fetcherstrasse 74, 01307, Dresden, Germany. 3. Department of Anesthesiology and Intensive Care Medicine, University Hospital of Leipzig, Liebigstrasse 20, 04103, Leipzig, Germany. 4. Department of Visceral, Transplantation, Vascular and Thoracic Surgery, University Hospital of Leipzig, Liebigstrasse 20, 04103, Leipzig, Germany. Maximilian.Brunotte@medizin.uni-leipzig.de. 5. Department of Surgery, University Hospital of Leipzig, Liebigstrasse 20, 04103, Leipzig, Germany. Maximilian.Brunotte@medizin.uni-leipzig.de. 6. Department of Gastroenterology and Rheumatology, University Hospital of Leipzig, Liebigstrasse 20, 04103, Leipzig, Germany. 7. Department of Internal Medicine, Neurology, Dermatology, Clinic for Endocrinology, Diabetology and Nephrology, University Hospital of Leipzig, Liebigstrasse 20, 04103, Leipzig, Germany.
Abstract
BACKGROUND: In contrast to insulin-dependent type 1 diabetes mellitus (T1DM), the indication for Simultaneous pancreas-kidney transplantation (SPK) in patients with type 2 diabetes mellitus (T2DM) is still ambiguous and wisely Eurotransplant (ET) only granted transplant-permission in a selected group of patients. However, with regard to improvement of metabolic conditions SPK might still be a considerable treatment option for lean insulin dependent type 2 diabetics suffering from renal disease. METHODS: Medical data (2001-2013) from all consecutive T1DM and T2DM patients who received a SPK or kidney transplant alone (KTA) at the University Hospital of Leipzig were analyzed. Donor, recipients and long-term endocrine, metabolic and graft outcomes were investigated for T1DM and T2DM-SPK recipients (transplanted upon a special request allocation by ET) and T2DM patients who received a KTA during the same period. RESULTS: Eighty nine T1DM and 12 T2DM patients received a SPK and 26 T2DM patients received a KTA. Patient survival at 1 and 5 years was 89.9 and 88.8% for the T1DM group, 91.7 and 83.3% for the T2DM group, and 92.3 and 69.2% for the T2DM KTA group, respectively (p < 0.01). Actuarial pancreas graft survival for SPK recipients at 1 and 5 years was 83.1 and 78.7% for the T1DM group and 91.7 and 83.3% for the T2DM group, respectively (p = 0.71). Kidney allograft survival at 5 years was 79.8% for T1DM, 83.3% for T2DM, and 65.4% for T2DM KTA (p < 0.01). Delayed graft function (DGF) rate was significantly higher in type 2 diabetics received a KTA. Surgical, immunological and infectious complications showed similar results for T1DM and T2DM recipients after SPK transplant and KTA, respectively. With regard to the lipid profile, the mean high-density lipoprotein (HDL)- cholesterol levels were significantly higher in T1DM recipients compared to T2DM patients before transplantation (p = 0.02) and remained significantly during follow up period. CONCLUSION: Our data demonstrate that with regard to metabolic function a selected group of patients with T2DM benefit from SPK transplantation. Consensus guidelines and further studies for SPK transplant indications in T2DM patients are still warranted.
BACKGROUND: In contrast to insulin-dependent type 1 diabetes mellitus (T1DM), the indication for Simultaneous pancreas-kidney transplantation (SPK) in patients with type 2 diabetes mellitus (T2DM) is still ambiguous and wisely Eurotransplant (ET) only granted transplant-permission in a selected group of patients. However, with regard to improvement of metabolic conditions SPK might still be a considerable treatment option for lean insulin dependent type 2 diabetics suffering from renal disease. METHODS: Medical data (2001-2013) from all consecutive T1DM and T2DMpatients who received a SPK or kidney transplant alone (KTA) at the University Hospital of Leipzig were analyzed. Donor, recipients and long-term endocrine, metabolic and graft outcomes were investigated for T1DM and T2DM-SPK recipients (transplanted upon a special request allocation by ET) and T2DMpatients who received a KTA during the same period. RESULTS: Eighty nine T1DM and 12 T2DMpatients received a SPK and 26 T2DMpatients received a KTA. Patient survival at 1 and 5 years was 89.9 and 88.8% for the T1DM group, 91.7 and 83.3% for the T2DM group, and 92.3 and 69.2% for the T2DMKTA group, respectively (p < 0.01). Actuarial pancreas graft survival for SPK recipients at 1 and 5 years was 83.1 and 78.7% for the T1DM group and 91.7 and 83.3% for the T2DM group, respectively (p = 0.71). Kidney allograft survival at 5 years was 79.8% for T1DM, 83.3% for T2DM, and 65.4% for T2DMKTA (p < 0.01). Delayed graft function (DGF) rate was significantly higher in type 2 diabetics received a KTA. Surgical, immunological and infectious complications showed similar results for T1DM and T2DM recipients after SPK transplant and KTA, respectively. With regard to the lipid profile, the mean high-density lipoprotein (HDL)- cholesterol levels were significantly higher in T1DM recipients compared to T2DMpatients before transplantation (p = 0.02) and remained significantly during follow up period. CONCLUSION: Our data demonstrate that with regard to metabolic function a selected group of patients with T2DM benefit from SPK transplantation. Consensus guidelines and further studies for SPK transplant indications in T2DMpatients are still warranted.
Entities:
Keywords:
Endocrine and metabolic long-term results; Immunosuppression; Pancreas transplantation; Type II diabetes
Authors: Nora Jahn; Maria Theresa Voelker; Sven Laudi; Sebastian Stehr; Stefan Schneeberger; Gerald Brandacher; Elisabeth Sucher; Sebastian Rademacher; Daniel Seehofer; Robert Sucher; Hans Michael Hau Journal: J Clin Med Date: 2022-05-03 Impact factor: 4.964
Authors: Krista L Lentine; Tarek Alhamad; Wisit Cheungpasitporn; Jane C Tan; Su-Hsin Chang; Matthew Cooper; Darshana M Dadhania; David A Axelrod; Mark A Schnitzler; Rosemary Ouseph; Franco H Cabeza Rivera; Bertram L Kasiske; Kenneth J Woodside; Ronald F Parsons Journal: Transplant Direct Date: 2020-08-21
Authors: Małgorzata Buksińska-Lisik; Przemysław Kwasiborski; Robert Ryczek; Wojciech Lisik; Artur Mamcarz Journal: J Clin Med Date: 2022-04-26 Impact factor: 4.964
Authors: Phuoc H Pham; Lily N Stalter; Eric J Martinez; Jesse F Wang; Bridget M Welch; Glen Leverson; Nicholas Marka; Talal Al-Qaoud; Didier Mandelbrot; Sandesh Parajuli; Hans W Sollinger; Dixon Kaufman; Robert R Redfield; Jon S Odorico Journal: Am J Transplant Date: 2021-01-15 Impact factor: 9.369
Authors: Robert Sucher; Tina Schiemanck; Hans Michael Hau; Sven Laudi; Sebastian Stehr; Elisabeth Sucher; Sebastian Rademacher; Daniel Seehofer; Nora Jahn Journal: J Clin Med Date: 2022-04-01 Impact factor: 4.241
Authors: Nora Jahn; Maria Theresa Völker; Sven Laudi; Sebastian Stehr; Stefan Schneeberger; Gerald Brandacher; Elisabeth Sucher; Sebastian Rademacher; Daniel Seehofer; Hans Michael Hau; Robert Sucher Journal: J Clin Med Date: 2022-06-13 Impact factor: 4.964
Authors: Hans Michael Hau; Markus Eckert; Sven Laudi; Maria Theresa Völker; Sebastian Stehr; Sebastian Rademacher; Daniel Seehofer; Robert Sucher; Tobias Piegeler; Nora Jahn Journal: J Clin Med Date: 2022-07-12 Impact factor: 4.964